OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, April 20, 2012

A prospective multicenter (phase IIIb) trialstudy of Treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis



A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis

This open-label multicenter phase-IIIb trial was conducted at 47 German institutions; the first 25 patients analyzed in this safety analysis were recruited in 10 centers.

Background  
Treosulfan, an alkylating agent, has demonstrated activity in recurrent ovarian carcinoma. It is equieffective as oral (p.o.) and intravenous (i.v.) formulation. To explore the preference and compliance of elderly patients regarding p.o. or i.v. treosulfan for the treatment of relapsed ovarian carcinoma, women aged 65 years or older were included in this prospective multicenter study. Since elderly patients usually have several concomitant diseases and experience more treatment toxicity, an interim safety analysis was planned and performed after 25 patients finished therapy to assess the tolerability of the treatment regimens.


Table 1 - 6 
  • Patient characteristics
  • Concomitant diseases
  • Treatment delivery
  • Reasons for early therapy discontinuation [less than 12 cycles (i.v.) or 12 months of therapy 
  • Non-hematological toxicities: highest grade per patient (in alphabetic order)
  • Hematological toxicities: highest grade per patient
"Altogether 16 serious adverse events (SAE) were documented for nine patients. The predominant reason for SAE-reporting was hospitalization (14 reports). Death was the matter for the remaining 2 SAEs. An additional patient was hospitalized due to progressive disease and died in hospital. In all 3 cases, death was concerned as not related to study medication and progress of the underlying malignant tumor was stated as cause of death."



"In summary, the observed toxicities were in the same range as reported in previous studies with significantly younger patients and less comorbidity or with old women having received fewer previous lines of chemotherapy.
There were no unexpected hematological or non-hematological toxicities. Based on this safety analysis, treosulfan proved to be a safe and tolerable therapeutic option in elderly, heavily pretreated patients and the next step of study recruitment was initiated. Of note, the majority of patients in the interim safety population chose i.v. treosulfan over the oral application. Detailed analysis after completion of the trial will hopefully yield new insight into therapy preference and compliance of elderly patients with recurrent ovarian cancer."

Conflict of interest  The trial was supported by Medac GmbH.











Thursday, April 19, 2012

Selected abstracts submitted to the Fourth International Symposium on Hereditary Breast and Ovarian Cancer 2012| Authors | Current Oncology



Selected abstracts submitted to the Fourth International Symposium on Hereditary Breast and Ovarian Cancer | Authors | Current Oncology

Emerging Therapies for Ovarian Cancer - Chemotherapy Advisor



Emerging Therapies for Ovarian Cancer - Chemotherapy Advisor

Bevacizumab
Other Antiangiogenesis Agents
Poly(ADP-ribose) Polymerase Inhibitors
Other Novel Agents in Ovarian Cancer



 
printer-friendly (view all on one page): link

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer - Full Text View - ClinicalTrials.gov



Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer - Full Text View - ClinicalTrials.gov

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This study is currently recruiting participants.
Verified April 2012 by Stanford University

First Received on December 13, 2011.   Last Updated on April 18, 2012   History of Changes
Sponsor: Stanford University
Information provided by (Responsible Party): Stanford University
ClinicalTrials.gov Identifier: NCT01494012
  Purpose
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

FDA (U.S.) Safety Alert > Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume



Safety Alerts for Human Medical Products > Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume


[Posted 04/18/2012]
AUDIENCE: Risk Manager, Pain Management
ISSUE: Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.
BACKGROUND: The affected product is a prefilled glass cartridge for use with the Carpuject Syringe system. The affected lot number is 10830LL, with an expiration date of April 1, 2013. Morphine Sulfate Carpujects 4 mg/mL are packaged in Slim-Pak tamper detection packages with each box containing 10 Carpujects (NDC 0409-1258-30).
The affected lot was distributed in January 2012. It was initially distributed to wholesalers and a limited number of hospitals in Arizona, Colorado, Hawaii, Illinois, Indiana, Michigan, Minnesota, Ohio, Texas and Virginia.
RECOMMENDATION: Anyone with an existing inventory of affected product should stop use and distribution and quarantine the product immediately and call Stericycle at 1-888-912-7088 to arrange for the return of the product.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

abstract + links/podcast: Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base



Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base

Conclusion 
Our phase III randomized placebo-controlled clinical trial demonstrated that naproxen at a dose of 500 mg twice per day is effective in reducing the incidence and severity of pegfilgrastim-induced bone pain.

Footnotes

Seth's Blog: Bandits and philanthropists



Bandits and philanthropists:

The web is minting both, in quantity.

Bandits want something for nothing. They take. They take free content where they can find it. They fight for anonymity, for less community involvement. They want more than their fair share, and they walk past the busker, because they can hear him playing real good, for free.

The spammer is a bandit, stealing your attention because he can get away with it, and leaving nothing in return.

Philanthropists see a platform for giving. They support the tip jar. They argue for community standards and yes, for taxes that are more fair to the community. They support artists online, and when they can, they buy the book.

The artist who creates a video that touches you, or an infographic that informs you--she's giving more than she gets, leaving the community better than it was before she got there.

Both types have been around forever, of course. But the web magnifies the edges. It's easier than ever to be a free rider, to make your world smaller and to take. And easier than ever to be a big time contributor, even if you don't have any money. You can contribute your links or your attention or your energy...

The fascinating thing for me is how much more successful and happy the philanthropists are. It turns out that when you make the world smaller, you get to keep more of what you've got, but you end up earning a lot less (respect, connections, revenue) at the same time.

Canadian breast implant cohort: Extended follow-up of cancer incidence



Blogger's Note: prior Canadian patient-led lawsuits failed
                                 ~~~~~~~~~~~~~~~~~

Canadian breast implant cohort: Extended follow-up of cancer incidence:

Abstract

Cosmetic breast implants are not associated with increased breast cancer incidence, but variations of risk according to implant characteristics are still poorly understood. As well, the assessment of cancer risk for sites other than breast needs to be clarified. The purpose of this study was to fill these research gaps. This study presents an extended analysis of 10 more years of follow-up of a large Canadian cohort of women who received either cosmetic breast implants (n=24,558) or other cosmetic surgery (15,893). Over 70% of the implant cohort was followed for over 20 years. Cancer incidence among implant women was compared to those of controls using multivariate Poisson models and the general female population using the Standardized Incidence Ratios (SIRs). Women with breast implants had reduced rates of breast and endometrial cancers compared with other surgery women. Subglandular implants were associated to a reduced rate of breast cancer compared to submuscular implants (Incidence Rate Ratio (IRR) = 0.78, 95% CI= 0.63-0.96) and this reduction persisted over time. We observed a 7-fold increased rate (IRR = 7.36, 95% CI= 1.86-29.12) of breast cancer in the first five years after the date of surgery for polyurethane-coated subglandular implant women but this IRR decreased progressively over time (p value for trend = 0.02). We also observed no increased risk of rarer forms of cancer among augmented women. A reduction in breast cancer incidence was observed for women with subglandular implants relative to women with submuscular implants. Possible increase of breast cancer incidence shortly after breast augmentation with polyurethane implants needs to be verified.

FDA (U.S.) Press Announcements > U.S. Marshals seize ultrasound gel product at a New Jersey company



Press Announcements > U.S. Marshals seize ultrasound gel product at a New Jersey company

 FDA NEWS RELEASE
For Immediate Release: April 18, 2012
Media Inquires: Sarah Clark-Lynn, 301-796-9110, sarah.clark-lynn@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
U.S. Marshals seize ultrasound gel product at a New Jersey companyProduct samples revealed bacterial contamination

JCO Editorial (re: Ontario/Pritchard et al) [18F]Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Breast Cancer: When… and When Not?



[18F]Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Breast Cancer: When… and When Not?

"....It has taken a relatively long time to generate the data needed to guide appropriate use of FDG PET/CT for breast cancer for all phases of the disease. The task is still not quite complete but is propelled by studies such as Pritchard et al.6 We hope that the approach for directing new imaging procedures into clinical practice will continue to improve and be ready when the next imaging breakthrough emerges."

"Diagnostic imaging plays an important role in the care of patients with breast cancer and is used for breast cancer detection, diagnosis, staging, and therapeutic response evaluation.1 Advances in imaging technology, especially relatively newer technologies such as magnetic resonance imaging (MRI) and positron emission tomography without or with integrated computed tomography (PET or PET/CT) provide powerful diagnostic tools, but also generate questions and controversy regarding where and when to use these new modalities. Early studies of new imaging approaches most often come from centers that are scientifically invested in the development of the technology. Typically, small and highly selected patient populations are evaluated, and these preliminary studies often indicate excellent diagnostic performance. Later on, when large multicenter trials are performed with more clinically representative patient populations, the new test invariably performs less well. Nevertheless, the excitement surrounding early results from a new imaging technology and the increasing public access to these early results fuel the desire by patients for access to new forms of diagnostic imaging. Physicians and patients share the wish for diagnostic certainty in excluding cancer spread at the time of diagnosis and may reason that a purely diagnostic procedure, even if untested, can do no harm. These factors, combined with the challenge and expense of carrying out larger scale diagnostic imaging trials, can lead to the early adoption of new imaging studies into clinical practice, often before their performance and optimal use have been fully determined. However, ......."

abstract: Prospective Study of 2-[18F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study



Prospective Study of 2-[18F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study

 Purpose 2-[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is potentially useful in assessing lymph nodes and detecting distant metastases in women with primary breast cancer.


Conclusion
FDG-PET is not sufficiently sensitive to detect positive axillary lymph nodes, nor is it sufficiently specific to appropriately identify distant metastases. However, the very high positive predictive value (96%) suggests that PET when positive is indicative of disease in axillary nodes, which may influence surgical care.

JCO: Palliative Sedation: When and How? Commentary including references



 Blogger's Note: 
“Not everything that can be counted counts and not everything that counts can be counted.” Albert Einstein

                                           ~~~~~~~~~~~~~~
Commentary (on Maltoni et al):  Palliative Sedation: When and How?

REFERENCES



abstract: Postoperative venous thromboembolism predicts survival in cancer patients



Postoperative venous thromboembolism predicts survi... [Ann Surg. 2012]

OBJECTIVES:

To determine whether a postoperative venous thromboembolism (VTE) is associated with a worse prognosis and/or a more advanced cancer stage and to evaluate the association between a postoperative VTE and cancer-specific survival when known prognostic factors, such as age, stage, cancer type, and type of surgery, are controlled.

CONCLUSIONS:

Postoperative VTE in oncology patients with limited disease and a complete surgical resection is associated with an inferior cancer survival. A postoperative VTE remains a poor prognostic factor, even when controlling for age, stage, cancer type, and surgical procedure further supporting an independent link between hypercoagulability and cancer survival.

JNCI J Natl Cancer Inst - audio/podcast - JNCI PODCAST News Summaries for Issue 9 The Efficacy of Cancer Vaccines - Dr. Jeffrey Schlom talks about therapeutic cancer vaccines



Blogger's Note: comments in interview include references to prostate, FAP (genetics/colorectal cancer) & high risk ovarian/breast; note also comments regarding the use of cancer vaccines in early stage cancers


JNCI PODCAST

The Efficacy of Cancer Vaccines- Dr. Jeffrey Schlom talks about therapeutic cancer vaccines

abstract: If patient-reported outcome measures are considered key health-care quality indicators, who is excluded from participation? - Health Expectations



If patient-reported outcome measures are considered key health-care quality indicators, who is excluded from participation?  - Health Expectations 
 

Abstract

Patient-reported outcome measures have received increasing attention with regard to ensuring quality improvement across the health service. However, there is a risk that people with disabilities and low literacy are systematically excluded from the development of these measures as well as their application in clinical practice. This editorial highlights some of these risks and the potential consequences of exclusion for these groups.

Wednesday, April 18, 2012

Oncology Times - Friday, April 13, 2012 SGO Restructures to Incorporate a 501(c)(6)



Oncology Times
Friday, April 13, 2012
SGO Restructures to Incorporate a 501(c)(6)

A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov



A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
This study is currently recruiting participants.
Verified March 2012 by University of Michigan Cancer Center

First Received on March 30, 2012.   Last Updated on April 16, 2012   History of Changes
Sponsor: University of Michigan Cancer Center
Information provided by (Responsible Party): Ronald Buckanovich, University of Michigan Cancer Center
ClinicalTrials.gov Identifier: NCT01579812
  Purpose
The primary objective of this study is to determine if metformin administered as the time of traditional adjuvant chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at 18 months compared to controls.

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavi - GOGty Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy - Full Text View - ClinicalTrials.gov



 WebMd:  ACETYL - L - CARNITINE (including other names)

                            ~~~~~~~~~~~~~~~~~~~~

This study is not yet open for participant recruitment.
Verified April 2012 by National Cancer Institute (NCI)

First Received on December 14, 2011.   Last Updated on April 17, 2012   History of Changes

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy - Full Text View - ClinicalTrials.gov

Purpose
RATIONALE: Acetyl-L-carnitine hydrochloride may prevent or lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine hydrochloride is more effective compared to a placebo in preventing peripheral neuropathy caused by chemotherapy.
PURPOSE: This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer undergoing chemotherapy.

Does “Cancer” – The Word – Properly Explain “Cancer” – the Disease?



Does “Cancer” – The Word – Properly Explain “Cancer” – the Disease?:
by Jonathan Klein, MD
Often times, after explaining a diagnosis and treatment plan to a patient, physicians hear some variation on “my brother/sister/parent/friend/co-worker had cancer and received radiation/surgery/phase I clinical trial medication. Why am I not receiving this?” The answer may revolve around the idea that different cancers, even different cancers arising from the same part of the body, can be wildly different in biology, treatment, and prognosis. We obviously want to ensure that patients understand their options so that they can make informed decisions about their own care, but couldn’t the medical community do a better job of conveying this concept to the public even before people end up in our clinics?

We use the catch-all term “cancer” to refer to diseases within the body arising from uncontrollably dividing cells. It is a term familiar to everyone, and a diagnosis of cancer is a useful shorthand – it’s concise, easy to understand, and conveys a sense of seriousness around what lies ahead. But beyond that initial purpose, it’s largely insufficient.

Potentially Dangerous Complementary and Alternative Medicine (CAM) Use by Ovarian Cancer Patients | Abstract



Potentially Dangerous Complementary and Alternative Medicine (CAM) Use by Ovarian Cancer Patients

Abstract

Objective: 
The use of complementary or alternative medicine (CAM) has increased greatly over the last decade. Although many CAM activities are unlikely to increase a patient's risk for adverse events with conventional treatment for cancer, this is not necessarily true of ingestible CAM treatments such as herbal remedies, teas, and other supplements. This study surveyed women with ovarian cancer in order to evaluate the use of herbs and supplements that might place them at increased risk at the time of their surgery for ovarian cancer.  

Methods: 
A total of 219 women with ovarian cancer, who had received care from one of two participating oncology practices, were surveyed. 

Results: 
Of the women who reported having had surgery to treat their ovarian cancer (n=209), 65 (31%) reporting using one or more herbs or supplements that have been hypothesized to increase their risk for adverse outcomes. In almost all cases the risks associated with these substances were elevated risks for excessive bleeding.  

Conclusions: 
The use of herbs and supplements that might increase risks associated with excessive bleeding during gynecologic cancer surgery is common. Further research is needed to better understand the risks associated with use of herbs and supplements among women approaching surgery
. (J GYNECOL SURG 28:1)

Medscape: New Map of Breast Cancer Identifies 10 Disease Subtypes



Blogger's Note: references Oncotype DX and MammaPrint

New Map of Breast Cancer Identifies 10 Disease Subtypes

Oncofertility Education Modules: A presentation by Dr. Hananel Holzer



Oncofertility Education Modules: A presentation by Dr. Hananel Holzer:


Resident Module – Fertility#1
Resident Module – Fertility#2a
Resident Module – Fertility#2b

Resident Module – Fertility#3


by Monisha Sudarshan, MD
As one walks into Dr.Holzer’s office, his passion and love for helping patients with fertility issues is clear. Among the many honors and thank you notes, sits a small decorative baby carriage with the words engraved “Doctors are known to heal, you are known to create miracles”. Dr. Holzer is the Medical Director of the MUHC (McGill University Health Centre) Reproductive Centre and one of the pioneers in oncofertility. In fertility management, he describes every couple as a “new story” however, oncofertility presents its own unique challenges and complexities for the patient and physician population. Dr.Holzer advises his patients that the first and foremost importance is to fight the cancer; fertility represents an important aspect but is not the primary priority. One of his goals is also to educate and bring awareness to cancer physicians and residents about the options of fertility preservation for the younger oncology population and is working on creating easy, timely access for referral of these patients to expert centers. Continuing his educational endeavour, he has designed expert teaching modules targeted for resident education in oncology and fertility and to spark interest in this interesting and rapidly growing field. Modules begin with basic physiological changes with chemotherapy and radiotherapy, progress to current options in fertility preservation and the experience at the McGill University Health Center. Continue to stay tuned for more knowledge on this important and stimulating topic within oncology.

Clinical Performance Allocation April 2012 report - CIHI



Clinical Performance Allocation









Where the Oldest Die Now - NYTimes.com



Where the Oldest Die Now - NYTimes.com

".... But if people are being shuttled from home to hospital to nursing home (and possibly around again) during their last days and weeks, that’s nothing to celebrate. “Site-of-death data only tells you where you are at time of death, but nothing about the transitions leading to that point,” Dr. Teno said....."

Leading Provider of Doctor-Formulated Nutritional Supplements Gets America Moving in a Healthy... -- POTOMAC, Md., April 18, 2012 /PRNewswire/ --



Leading Provider of Doctor-Formulated Nutritional Supplements Gets America Moving in a Healthy... -- POTOMAC, Md., April 18, 2012 /PRNewswire/ --

Opinion: Data to Knowledge to Action (pizza? lost friend? genomics.....)



Opinion: Data to Knowledge to Action:

Pizza on Tuesday within 2 miles of home?  There is a search for that.  Find a long lost high school friend or an out of print book? There are searches for that.  Correlating genomic information with proteomics data, patient information, and drug trial results?  You’re on your own.  It is ironic and lamentable that internet queries can get you information on so many things, yet the scientific data that are crucial to finding cures for numerous diseases are often buried in an unusable format on a hard drive in somebody’s garage.

press release: Problems in cancer care are not uncommon



 Blogger's Opinion: although this article focuses on breast cancer, there is of course a common theme, attention is deserved for those with less common/rare cancers as the dichotomies in care (access, research, outcomes.....) should be obvious

                        ~~~~~~~~~~~~~~~~~

Problems in cancer care are not uncommon

Public release date: 17-Apr-2012

Difficulties occur more often in communication than in medical care

Cancer care is increasingly complex, and as many as one in five cancer patients may experience "breakdowns" in their care, according to a new study in the Journal of Clinical Oncology. Such breakdowns include communication problems between patients and their care providers, as well as more traditional medical errors; both types of problems can create significant harms. In the study, communication problems outnumbered problems with medical care.

Kathleen Mazor, EdD, Assistant Director of the Meyers Primary Care Institute, in Worcester, MA, led the study, with researchers from the University of Washington, Group Health, and Kaiser Permanente. Their study was a project of the Cancer Research Network's Cancer Communication Research Center. They found that problematic events led to varied consequences, such as additional medical care, delayed recovery, emotional distress, and persistent damage to the relationship between patients and their doctors.

"For me, the take-home message is it's critical for us to listen to patients as we try to improve care," Dr. Mazor said. "The patients we spoke with were generous, articulate, and thoughtful in recounting their experiences, and were glad to share their stories because they wanted to make a difference. We also heard a lot of stories about physicians, nurses, and others who really helped make things better—in the aftermath of a problem or even in the absence of a problem."

Examining actions patients took following a breakdown, the research team found that only 13 percent formally reported the problem, choosing instead to focus on their health and their future. Nearly all patients indicated that the problem spurred them to take positive steps in their health care behaviors, such as asking more questions or researching symptoms and treatments. However, 10 percent of patients reported they became more hesitant to seek care

The study used telephone interviews rather than medical-chart documentation to understand how patients perceived their care experiences.

"It's vital that we hear directly from the patients," noted study co-author Sarah M. Greene, MPH. "The communication problems probably wouldn't have appeared in their medical record. But to the patient, they are as significant as a clinical adverse event, like a wrong dose of chemotherapy." Ms. Greene is a research associate at Group Health Research Institute in Seattle.

Both patients and clinicians need new ways to provide negative and positive feedback about cancer care, according to the authors, and these systems should include some patient and clinician education. Additionally, the study team noted that patients' perceptions of problems may differ from clinicians' perspectives, so educating clinicians is equally critical. The health systems in this study are currently exploring strategies to encourage both patients and clinicians to openly communicate about their care experiences and expectations.

This study "reminds us that substantial work is needed to optimize breast cancer care and, most importantly, communication," Jeffrey Peppercorn, MD, MPH, of Duke University Medical Center, wrote in an accompanying editorial.
###
The National Cancer Institute funded the study.
Dr. Mazor's and Ms. Greene's co-authors were Douglas Roblin, PhD, and Josephine Calvi, MPH, of Kaiser Permanente Georgia, in Atlanta; Kathryn Horner, MPH, of Group Health Research Institute; Celeste Lemay, RN, and Cassandra Firneno, BS, of Meyers Primary Care Institute, in Worcester, Massachusetts; and Thomas H. Gallagher, MD, an affiliate investigator at Group Health Research Institute who is based at the University of Washington School of Medicine's Department of Medicine.

Journal of Clinical Oncology The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer. For more information, see http://jco.ascopubs.org/
 
HMO Research Network The HMO Research Network is a consortium of 19 health care delivery organizations with both defined patient populations and formal, recognized research capabilities. The Network's vision is to be the research partner of choice for those seeking to shape health and health care delivery. For more information, see http://www.hmoresearchnetwork.org
 
Meyers Primary Care Institute The Meyers Primary Care Institute was established in 1996 as a joint venture of Fallon Clinic (now Reliant Medical Group), Fallon Community Health Plan, and the University of Massachusetts Medical School. The Institute's mission is to promote primary care practice through innovative research and educational initiatives. For more information, see http://www.umassmed.edu/meyers/index.aspx
Kaiser Permanente Georgia's Center for Health Research Kaiser Permanente Georgia's Center for Health Research conducts professionally independent, public domain research and disseminates its findings in the scholarly literature and scientific community. For more information, see http://www.kpchr.org/research/public/default.aspx
 
Group Health Research Institute Group Health Research Institute is the research arm of Seattle-based Group Health Cooperative, a consumer-governed, nonprofit health care system. Founded in 1947, Group Health Cooperative coordinates health care and coverage. Group Health Research Institute changed its name from Group Health Center for Health Studies in 2009. Since 1983, the Institute has conducted nonproprietary public-interest research on preventing, diagnosing, and treating major health problems. Government and private research grants provide its main funding. For more information, see http://www.grouphealthresearch.org
 
UW Medicine The UW Medicine health system includes Harborview Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, UW Medical Center, UW Neighborhood Clinics, UW Physicians, UW School of Medicine, and Airlift Northwest. UW Medicine also shares in the ownership and governance of Children's University Medical Group and Seattle Cancer Care Alliance, a partnership among UW Medicine, Fred Hutchinson Cancer Research Center, and Seattle Children's. UW Medicine has major academic and service affiliations with Seattle Children's, Fred Hutchinson Cancer Research Center, the Veteran's Affairs Puget Sound Health Care System in Seattle, and the VA Hospital in Boise, Idaho. The UW School of Medicine is the top public institution for biomedical research in funding received from the National Institutes of Health. For more information about UW Medicine, visit http://uwmedicine.washington.edu.




abstract: [Clinical aspects of familial ovarian cancer - current status and issues in Japan] (focus on brca)



Blogger's Note: the [ ] indicates translated version


[Clinical aspects of familial ovarian cancer - current status and issues in Japan]

Abstract
Familial ovarian cancer occurs as part of two genetically distinct syndromes: hereditary breast and ovarian cancer(HBOC) and hereditary nonpolyposis colorectal cancer(HNPCC) (Lynch Syndrome) .

HBOC caused by inherited mutations of BRCA1/2 and HNPCC caused by mismatch-repair genes are considered responsible for about 65 to 75% and 10 to 15% of familial ovarian cancers, respectively. Germline mutations of BRCA1 are considered responsible for about 50% of ovarian cancer families and 80% of breast-ovarian cancer families. BRCA2 mutations are less common than BRCA1 mutations in ovarian cancer families. A high proportion of serous adenocarcinomas at an advanced stage has been reported with BRCA-related ovarian cancers in several studies. It is controversial whether BRCA-related ovarian cancer patients carry a better prognosis despite the aggressive tumor-pathological characteristics of their disease, compared to sporadic cases. However, a good therapeutic response may be attributable to platinum-based chemotherapy. Recently in Japan, gene testing of BRCA1/2 has been available as a routine clinical test for diagnosing ovarian cancer families. Because the mutation spectrum of BRCA1/2 in Japanese was different from that of non-Ashkenazi individuals, the clinical application of BRCA1/2 gene testing for Japanese has been advocated. Approximately 1-5% of ovarian cancer pa-tients in Japan are thought to have a family history of breast and/or ovarian cancer. The prevalence of deleterious mutations of BRCA1/2 in Japanese was reportedly significantly higher than that of non-Ashkenazi individuals despite the low frequency of familial cases in Japan. Although the age at diagnosis of ovarian cancers with BRCA1/2 mutation in the United States was earlier than those of the sporadic cases, there were no differences among Japanese. These results suggest that clinical and genetic aspects of BRCA-related ovarian cancer of the Japanese are different from those of Caucasians.

A serious issue in this field is how the results will lead to a basis for the clinical application of a cancer prevention strategy targeting BRCA mutation carriers in Japanese.


Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation.



Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation.:

Progress against cancer through prevention and treatment is often measured by survival statistics only instead of analyzing trends in incidence, survival and mortality simultaneously because of interactive influences. This study combines these parameters of major cancers to provide an overview of the progress achieved in the Netherlands since 1989 and to establish in which areas action is needed. The population-based Netherlands Cancer Registry and Statistics Netherlands provided incidence, 5-year relative survival and mortality of 23 major cancer types. Incidence, survival and mortality changes were calculated as the estimated annual percentage change. Optimal progress was defined as decreasing incidence and/or improving survival accompanied by declining mortality, and deterioration as increasing incidence and/or deteriorating survival accompanied by increasing mortality rates. Optimal progress was observed in 12 of 19 cancer types among males: laryngeal, lung, stomach, gallbladder, colon, rectal, bladder, prostate and thyroid cancer, leukemia, Hodgkin and non-Hodgkin lymphoma. Among females, optimal progress was observed in 12 of 21 cancers: stomach, gallbladder, colon, rectal, breast, cervical, uterus, ovarian and thyroid cancer, leukemia, Hodgkin and non-Hodgkin lymphoma. Deterioration occurred in three cancer types among males: skin melanoma, esophageal and kidney cancer, and among females six cancer types: skin melanoma, oral cavity, pharyngeal, esophageal, pancreatic and lung cancer. Our conceptual framework limits misinterpretations from separate trends and generates a more balanced discussion on progress.

Tuesday, April 17, 2012

open access: Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging



fulltext.pdf (application/pdf Object)

press release: Consumer Activity on Social Media Sites Dwarfs That of Healthcare Companies, Finds New PwC Study on Social Media in Healthcare



Consumer Activity on Social Media Sites Dwarfs That of Healthcare Companies, Finds New PwC Study on Social Media in Healthcare

NEW YORK, April 17, 2012 /PRNewswire/ -- Social media is changing the nature of healthcare interaction, and health organizations that ignore this virtual environment may be missing opportunities to engage consumers, according to a new report by the Health Research Institute (HRI) at PwC US entitled, "Social media likes healthcare: From marketing to social business." The report found that social media activity by hospitals, health insurers and pharmaceutical companies is miniscule compared to the activity on community sites......

The consumer survey found:
  • One-third of consumers now use social media sites such as Facebook, Twitter, YouTube and online forums for health-related matters, including seeking medical information, tracking and sharing symptoms, and broadcasting how they feel about doctors, drugs, treatments, medical devices and health plans.
  • Four in 10 consumers say they have used social media to find health-related consumer reviews (e.g. of treatments or physicians); one in three have sought information related to other patients' experiences with their disease; one in four have "posted" about their health experience; and one in five have joined a health forum or community.
  • When asked how information found through social media would affect their health decisions, 45 percent of consumers said it would affect their decision to get a second opinion; 41 percent said it would affect their choice of a specific doctor, hospital or medical facility; 34 percent said it would affect their decision about taking a certain medication; and 32 percent said it would affect their choice of a health insurance plan.
  • While 72 percent of consumers said they would appreciate assistance in scheduling doctor appointments through social media channels, nearly half said they would expect a response within a few hours.
  • As is the case more broadly, young adults are leading the social media healthcare charge. More than 80 percent of individuals between the ages of 18 and 24 said they were likely to share health information through social media channels and nearly 90 percent said they would trust information they found there. By comparison, less than half (45 percent) of individuals between the ages of 45 and 64 said they were likely to share health information via social media.

Diffusion-weighted Imaging Study in Cancer of the Ovary - Full Text View - ClinicalTrials.gov



Diffusion-weighted Imaging Study in Cancer of the Ovary - Full Text View - ClinicalTrials.gov

Diffusion-weighted Imaging Study in Cancer of the Ovary (DISCOVAR)
This study is not yet open for participant recruitment.
Verified March 2012 by Institute of Cancer Research, United Kingdom


First Received on November 18, 2011.   Last Updated on March 30, 2012   History of Changes
Sponsor: Institute of Cancer Research, United Kingdom
Collaborators: Cancer Research UK
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
Imperial College Healthcare NHS Trust
Northumbria Healthcare NHS Foundation Trust
Information provided by (Responsible Party): NdeSouza, Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT01505829
  Purpose
This project seeks to develop a quantitative imaging biomarker for evaluating and monitoring treatment response in ovarian cancer metastases and assess its potential in monitoring treatment response. This will involve standardising DW-MRI for the abdomen and pelvis across multiple centres and platforms, assessing reproducibility of the measurement in patients planned for neoadjuvant chemotherapy and assessing its utility as an early response biomarker in patients with platinum-sensitive relapse due to receive therapy with carboplatin. Scanning measurements will be correlated with histopathological markers in tumour samples in order to link the biomarker with response mechanisms.

Condition
Ovarian Cancer
Peritoneal Metastases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging.

financial news: ImmunoGen Says IND For Anticancer Compound IMGN853 Is Now Active



ImmunoGen Says IND For Anticancer Compound IMGN853 Is Now Active


(RTTNews.com) - ImmunoGen, Inc. (IMGN) announced that the Investigational New Drug, or IND, application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, non-small cell lung cancer and other epithelial malignancies which over-express folate receptor 1, or FOLR1.
The company expects Phase I evaluation of IMGN853 to commence in the middle of 2012.....

Pinterest: Lynch Syndrome



Lynch Syndrome

Health Imaging: Uptick in colorectal cancer among under-50 crowd poses questions for researchers (Lynch Syndrome....)



Uptick in colorectal cancer among under-50 crowd poses questions for researchers

 ....Whatever the cause, the rate of colorectal cancer in young adults has increased to the point where nearly 10 percent of new diagnoses are in patients younger than 50. Most of these patients were diagnosed in their forties, but the disease has been found in patients in their twenties and thirties.......Another troubling recent finding is that when colorectal cancers are diagnosed in younger patients, they are more likely to be at an advanced stage of the disease. A study published Feb. 13 online in Archives of Internal Medicine found 63 percent of colon cancers and 57 percent of rectal cancers are stage III or IV at diagnosis......“The important thing for radiologists would be the notion that certain individuals, because of their age, may be denied radiology procedures by insurance companies,” she said.......

open access: What do surgical trainees think about patient safety culture, and is this different from their consultants?



What do surgical trainees think about patient safety culture, and is this different from their consultants?

Abstract

Introduction Little is known about the patient safety culture within surgical departments in UK hospitals. What has been done to date is to survey only permanent senior staff opinion of the safety culture in their institution. This study surveyed both consultant and trainee views on perceived patient safety and compared the results between these two groups. 

Material and methods The previously validated Team Work and Safety Climate Questionnaire was configured in Survey Monkey format and sent to all surgical trainees and consultant surgeons in the South West Strategic Health Authority. Two reminders were sent to achieve as high a return rate as possible. 

Results Two hundred and ninety-six replies were received. Forty-four percent of trainees and 30% of consultants responded to the survey. Consultants consistently rated a higher safety culture than surgical trainees. Only 2.9% of trainees believe their patient safety concerns would be acted upon by hospital management. There is notable variation in perceived patient safety culture between hospitals. 

Conclusion This study has suggested that the patient safety culture in hospitals, within a Strategic Health Authority, is variable and sub-optimal when viewed by surgical trainees and their consultants. This study also provides some evidence that the perception of patient safety in an organization varies according to clinical experience. As trainees deliver a great deal of clinical care, surveys of safety culture should include this group. As perceived patient safety culture is correlated to clinical outcomes, validated safety surveys might form part of the assessment of a hospital's performance, along with outcome and patient satisfaction.

Introduction

Medical errors are a major cause of mortality and morbidity. The National Patient Safety Agency (NPSA) estimates that 10% of all hospital admissions suffer an adverse event defined as a medical error that results in harm to the patient. One percent of all admissions die as a result of an adverse event. In practice this means that in England and Wales 300,000 adverse events and 30,000 deaths are recorded every year. This figure of 30,000 deaths a year is a greater number of deaths than the combined annual mortality from colorectal, prostate and breast cancer.1 Even these striking figures may be underestimating the extent of the problem because recent studies in the surgical literature2 indicate the adverse event rate could even be as high as 20%...........

Cancer Prevention Research: Does Vitamin E Prevent or Promote Cancer?



Abstract

The cancer preventive activity of vitamin E has been suggested by many epidemiologic studies. However, several recent large-scale human trials with α-tocopherol, the most commonly recognized and used form of vitamin E, failed to show a cancer preventive effect. The recently finished follow-up of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) even showed higher prostate cancer incidence in subjects who took α-tocopherol supplementation. The scientific community and the general public are faced with a question: “Does vitamin E prevent or promote cancer?” Our recent results in animal models have shown the cancer preventive activity of γ- and δ-tocopherols as well as a naturally occurring mixture of tocopherols, and the lack of cancer preventive activity by α-tocopherol. On the basis of these results as well as information from the literature, we suggest that vitamin E, as ingested in the diet or in supplements that are rich in γ- and δ-tocopherols, is cancer preventive; whereas supplementation with high doses of α-tocopherol is not. Cancer Prev Res; 1–5. ©2012 AACR.

Monday, April 16, 2012

open access: PLoS ONE: Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear



PLoS ONE: Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear

"......A major finding indicating pathogenetic or toxic properties of nitrated proteins was presented recently: assembly of alpha-synuclein and fibrinogen were deteriorated by nitration of only a small fraction of proteins [25], [32]. As for fibrinogen, nitration is accelerating the rate of fibrin clot formation [33]. It cannot be ruled out, therefore, that nitration of Avastin® may lead to side effects based upon probable disturbed protein-protein interactions as aggregations that in turn may lead to a series of complications as listed in the drug information sheet.
As to the underlying cause of tyrosine nitration it remains open, whether it can be considered as a post-translational modification of the immunoglobulin Avastin® or technical in nature, or both [34]-[38].
Taken together, it remains unclear if the observed nitrations and other PMs detected on Avastin® may be responsible for different biological or pharmacotoxicological properties and effects. Quantification of nitrations and their presence in several batches of the product has to be taken into considerations on probable toxicity as well, but corresponding in vivo analyses based upon these findings should be carried out by the manufacturers to probably save this protein drug that may have strong potential in tumor therapy."

media: Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic (Vintafolide/Endocyte)



Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic

 Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion... Under the terms of the deal, Merck, through a subsidiary, will get worldwide rights to develop and commercialize vintafolide for ovarian cancer that’s resistant to platinum-based chemotherapy treatment. Endocyte (NASDAQ:ECYT), the Indiana-based cancer therapeutics developer, will receive a $120 million up-front payment and is eligible for milestone payments of up to $880 million if it achieves certain development, regulatory and commercialization milestones for vintafolide for a total of six cancer indications, according to a company statement......

"...The clinical trials for both maladies will also use etarfolatide, a noninvasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells.....

JCO The Art of Oncology (2010) Art Informs Medicine (ovarian cancer)



Art Informs Medicine

"...... The artist, whose work is on exhibit, is here by appointment. She was diagnosed with ovarian cancer 2 years ago.......

(2003) A Couple With Cancer: Conflicting Wishes, Joint Decisions (ovarian cancer) JCO Art of Oncology



A Couple With Cancer: Conflicting Wishes, Joint Decisions

"JULIE AND ROBERT arrived at the hospital from a small country town concerned about Julie’s swollen abdomen and her inability to eat. Scans demonstrated ascites and bilateral ovarian masses, but a small liver lesion and a thickened stomach wall did not fit with a typical ovarian cancer. After discussing the likely diagnosis of cancer, possibly gastric, the gynecological oncologist deferred surgery, organized an endoscopy, and requested a medical oncology opinion........"

(2005) Cancer Patients' and Patient Advocates' Perspectives on a Novel Information Source: A Qualitative Study of The Art of Oncology, When the Tumor Is Not the Target



Cancer Patients' and Patient Advocates' Perspectives on a Novel Information Source: A Qualitative Study of The Art of Oncology, When the Tumor Is Not the Target

"....A special section of the Journal of Clinical Oncology entitled “The Art of Oncology: When the Tumor Is Not the Target” was initiated in January 2000 to facilitate discussion among professionals regarding improved end-of-life patient care. The articles published in this journal section, which were written by and for oncology health care professionals, were compiled into an anthology, which is also entitled The Art of Oncology: When the Tumor Is Not the Target,7 and sent to all members of the American Society of Clinical Oncology in May 2003. The anthology is divided into the following four sections: (1) end-of-life issues; (2) emotions of the oncologist; (3) hospice and symptom control; and (4) survivorship issues. The articles included in the anthology were developed from the beginning as informational sources that could potentially be of value, not only to professional audiences, but to select members of the lay public as well, including patients facing end-of-life issues and their families. In the current study, we interviewed advanced cancer patients and patient advocates about their personal perspectives on this anthology (ovarian cancer patients included).....





JCO series: Art of Oncology (3) open access



 Blogger's Note: the Art of Oncology series, formerly known as The Art of Oncology, When the Tumor is Not the Target represents a collection of integrated clinical and human interest stories, typically written from the healthcare provider's perspective, all involving special patients/situations/lasting memories; searching the archives of the series you will find ovarian cancer in this series

JCO Early Release Articles (date view)

April 16, 2012

Discussions: More On Dichloroacetate (DCA) In Cancer Treatment



Blogger's Note: background - the debates surrounding DCA include some opinions that because the drug is readily available and cheap, the role for cancer integration (manufacturing/pharma) is the reason there have been no advances in DCA research; the U of Alberta seems to be one exception (included in the discussion/s)

More On Dichloroacetate (DCA) In Cancer Treatment

audio/video/text: Topol on The Creative Destruction of Medicine (technology/social networks/patients sharing data/Patients Like Me, young patients, privacy ...)



(Dr) Topol on The Creative Destruction of Medicine

eg. MS/Facebook (Canada/stents/Facebook; I use this as an example (there are others in the interview) as the social networks moved forward clinical trials for MS patients where no support existed prior.....)

numerous videos: the Hastings Center - A Conversation with Leaders in Bioethics and Genetics | Help with Hard Questions



A Conversation with Leaders in Bioethics and Genetics | Help with Hard Questions

Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - MarketWatch



Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) - MarketWatch

Apr 16, 2012 (BUSINESS WIRE) -- Merck, known as MSD outside the United States and Canada, MRK +0.58% and Endocyte Inc. ECYT +103.95% , today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte's investigational companion diagnostic agent, etarfolatide (EC20).
"Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types," said Peter S. Kim, executive vice president and president Merck Research Laboratories. "This agreement underscores our strategy of building a portfolio of oncology therapeutics that employ a companion diagnostic to facilitate selection of those patients most likely to respond to treatment.".....

Mayo Clinic, Assured Diagnosis Inc. Announce Two New Private Health Insurance Products for Canadians - Press Release - Digital Journal



Mayo Clinic, Assured Diagnosis Inc. Announce Two New Private Health Insurance Products for Canadians - Press Release - Digital Journal


ROCHESTER, MN, and CALGARY, April 16, 2012 /CNW/ - Mayo Clinic and Assured Diagnosis Inc. (ADI) of Calgary, Alberta, announced today the launch of two new health insurance options that will provide more Canadians access to Mayo Clinic's expertise and care in the event of serious illness.
The two new offerings, MyCare Health Benefit Option (HBO) and MyCare Advantage Insurance, are now available to companies and associations as an addition to their benefit packages. Like the original MyCare plan, designed for individuals and families, these two new products are available nationwide in Canada, initially excluding Quebec..........

Thomson Reuters Announces 100 Top (U.S.) Hospitals Award Winners PRNewswire



 Blogger's Note: not a specific list for Cancer Centers but includes teaching centers

Thomson Reuters Announces 100 Top Hospitals Award Winners -- ANN ARBOR, Mich., April 16, 2012 /PRNewswire/ --

"The Thomson Reuters 100 Top Hospitals® study evaluates performance in 10 areas: mortality; medical complications; patient safety; average patient stay; expenses; profitability; patient satisfaction; adherence to clinical standards of care; post-discharge mortality; and readmission rates for acute myocardial infarction (heart attack), heart failure, and pneumonia. The study has been conducted annually since 1993."

For more information, please visit www.100tophospitals.com

press release: (OVA1) Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer



Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer


(press release) About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

open access: Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations (technical)



Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations - UKPMC Article - UK PubMed Central

Abstract
Utilizing the concept of synthetic lethality has provided new opportunities for the development of targeted therapies, by allowing the targeting of loss of function genetic aberrations. In cancer cells with BRCA1 or BRCA2 loss of function, which harbor deficiency of DNA repair by homologous recombination, inhibition of PARP1 enzymatic activity leads to an accumulation of single strand breaks that are converted to double strand breaks but cannot be repaired by homologous recombination. Inhibition of PARP has therefore been advanced as a novel targeted therapy for cancers harboring BRCA1/2 mutations. Preclinical and preliminary clinical evidence, however, suggests a potentially broader scope for PARP inhibitors. Loss of function of various proteins involved in double strand break repair other than BRCA1/2 has been suggested to be synthetically lethal with PARP inhibition. Inactivation of these genes has been reported in a subset of human cancers and might therefore constitute predictive biomarkers for PARP inhibition. Here we discuss the evidence that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers.
Key words: homologous recombination, PARP inhibitor, BRCA1, BRCA2, PTEN, PALB2, EMSY, double strand break repair